PINDOLOL - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for pindolol and what is the scope of patent protection?
Pindolol
is the generic ingredient in two branded drugs marketed by Ani Pharms, Aurobindo Pharma Usa, Bayshore Pharms Llc, Cosette, Mylan Pharms Inc, Nostrum Labs, Nostrum Labs Inc, Purepac Pharm, Sun Pharm Industries, Watson Labs, Zydus Pharms, and Novartis, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.There are eleven drug master file entries for pindolol. Nine suppliers are listed for this compound.
Summary for PINDOLOL
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 12 |
| NDAs: | 15 |
| Drug Master File Entries: | 11 |
| Finished Product Suppliers / Packagers: | 9 |
| Raw Ingredient (Bulk) Api Vendors: | 78 |
| Clinical Trials: | 16 |
| Patent Applications: | 6,366 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price trends for PINDOLOL |
| What excipients (inactive ingredients) are in PINDOLOL? | PINDOLOL excipients list |
| DailyMed Link: | PINDOLOL at DailyMed |
Recent Clinical Trials for PINDOLOL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Scotmann Pharmaceuticals | Phase 3 |
| Rawalpindi Medical College | Phase 3 |
| Weill Medical College of Cornell University | Phase 4 |
Pharmacology for PINDOLOL
| Drug Class | beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic beta-Antagonists |
Medical Subject Heading (MeSH) Categories for PINDOLOL
US Patents and Regulatory Information for PINDOLOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm Industries | PINDOLOL | pindolol | TABLET;ORAL | 074063-002 | Jan 27, 1994 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Nostrum Labs Inc | PINDOLOL | pindolol | TABLET;ORAL | 205415-002 | Jan 13, 2016 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Mylan Pharms Inc | PINDOLOL | pindolol | TABLET;ORAL | 074013-001 | Sep 24, 1992 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Bayshore Pharms Llc | PINDOLOL | pindolol | TABLET;ORAL | 211712-001 | Aug 1, 2019 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Aurobindo Pharma Usa | PINDOLOL | pindolol | TABLET;ORAL | 074019-002 | Sep 3, 1992 | AB | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Novartis | VISKEN | pindolol | TABLET;ORAL | 018285-002 | Sep 3, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Cosette | PINDOLOL | pindolol | TABLET;ORAL | 073661-002 | Oct 31, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PINDOLOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | VISKEN | pindolol | TABLET;ORAL | 018285-001 | Sep 3, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| Novartis | VISKEN | pindolol | TABLET;ORAL | 018285-002 | Sep 3, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
